Vidhya Karivedu1, Amit L Jain2, Thomas J Eluvathingal3, Abhinav Sidana4,5. 1. Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Columbus, OH, USA. 2. Department of Internal Medicine, University of Tennessee Health Science Center, Memphis, TN, USA. 3. Department of Radiology, University of Cincinnati, Cincinnati, OH, USA. 4. Division of Urology, University of Cincinnati, Cincinnati, OH, USA. sidanaav@ucmail.uc.edu. 5. Division of Urology, University of Cincinnati Cancer Institute, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0589, Cincinnati, OH, 45267, USA. sidanaav@ucmail.uc.edu.
Abstract
PURPOSE OF REVIEW: The clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of RCC due to its renal excretion. This review focuses on the clinical role and current status of FDG PET and PET/CT in RCC. RECENT FINDINGS: Studies investigating the role of FDG PET in localized RCC were largely disappointing. Several studies have demonstrated that the use of hybrid imaging PET/CT is feasible in evaluating the extra-renal disease. A current review of the literature determines PET/CT to be a valuable tool both in treatment decision-making and monitoring and in predicting the survival in recurrent and metastatic RCC. PET/CT might be a viable option in the evaluation of RCC, especially recurrent and metastatic disease. PET/CT has also shown to play a role in predicting survival and monitoring therapy response.
PURPOSE OF REVIEW: The clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of RCC due to its renal excretion. This review focuses on the clinical role and current status of FDG PET and PET/CT in RCC. RECENT FINDINGS: Studies investigating the role of FDG PET in localized RCC were largely disappointing. Several studies have demonstrated that the use of hybrid imaging PET/CT is feasible in evaluating the extra-renal disease. A current review of the literature determines PET/CT to be a valuable tool both in treatment decision-making and monitoring and in predicting the survival in recurrent and metastatic RCC. PET/CT might be a viable option in the evaluation of RCC, especially recurrent and metastatic disease. PET/CT has also shown to play a role in predicting survival and monitoring therapy response.
Authors: Suzanne C van Es; Adrienne H Brouwers; Shekar V K Mahesh; Annemarie M Leliveld-Kors; Igle J de Jong; Marjolijn N Lub-de Hooge; Elizabeth G E de Vries; Jourik A Gietema; Sjoukje F Oosting Journal: J Nucl Med Date: 2017-01-12 Impact factor: 10.057
Authors: Nathan Lawrentschuk; Aurora M T Poon; Serene S Foo; Lydia G Johns Putra; Carmel Murone; Ian D Davis; Damien M Bolton; Andrew M Scott Journal: BJU Int Date: 2005-09 Impact factor: 5.588
Authors: Ahmed Ebada Salem; Gabriel C Fine; Matthew F Covington; Bhasker R Koppula; Richard H Wiggins; John M Hoffman; Kathryn A Morton Journal: Cancers (Basel) Date: 2022-06-18 Impact factor: 6.575
Authors: Andrew J Wiele; Devaki Shilpa Surasi; Priya Rao; Kanishka Sircar; Xiaoping Su; Tharakeswara K Bathala; Amishi Y Shah; Eric Jonasch; Vince D Cataldo; Giannicola Genovese; Jose A Karam; Christopher G Wood; Nizar M Tannir; Pavlos Msaouel Journal: Cancers (Basel) Date: 2021-04-30 Impact factor: 6.639
Authors: M Fiedorowicz; M I Khan; D Strzemecki; J Orzeł; M Wełniak-Kamińska; A Sobiborowicz; M Wieteska; Z Rogulski; L Cheda; W Wargocka-Matuszewska; K Kilian; C Szczylik; A M Czarnecka Journal: Sci Rep Date: 2020-03-25 Impact factor: 4.379